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Abstract
Background: Mycobacterium bovis bacillus Calmette-Guérin (BCG) is known to be only partially effective in
inhibiting M. tuberculosis (MTB) multiplication in human. A new recombinant (r) urease-deficient BCG (BCG-dHCM)
that secretes protein composed of heat shock protein (HSP)70, MTB-derived CysO and major membrane protein
(MMP)-II was produced for the efficient production of interferon gamma (IFN-γ) which is an essential element for
mycobacteriocidal action and inhibition of neutrophil accumulation in lungs.
Methods: Human monocyte-derived dendritic cells (DC) and macrophages were differentiated from human
monocytes, infected with BCG and autologous T cells-stimulating activity of different constructs of BCG was
assessed. C57BL/6 mice were used to test the effectiveness of BCG for the production of T cells responsive to
MTB-derived antigens (Ags).
Results: BCG-dHCM intracellularly secreted HSP70-CysO-MMP-II fusion protein, and activated DC by up-regulating
Major Histcompatibility Complex (MHC), CD86 and CD83 molecules and enhanced various cytokines production
from DC and macrophages. BCG-dHCM activated naïve T cells of both CD4 and CD8 subsets through DC, and
memory type CD4+ T cells through macrophages in a manner dependent on MHC and CD86 molecules. These T
cell activations were inhibited by the pre-treatment of Ag-presenting cells (APCs) with chloroquine. The single
and primary BCG-dHCM-inoculation produced long lasting T cells responsive to in vitro secondarily stimulation
with HSP70, CysO, MMP-II and H37Rv-derived cytosolic protein, and partially inhibited the replication of
aerosol-challenged MTB.
Conclusions: The results indicate that introduction of different type of immunogenic molecules into a
urease-deficient rBCG is useful for providing polyclonal T cell activating ability to BCG and for production of T cells
responsive to secondary stimulation.
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Background
Tuberculosis is a chronic infectious disease, induced by
intracellular infection with MTB and is responsible for
around 1.4 million deaths yearly worldwide [1-3], and it is
estimated that one-third of the global populations is la-
tently infected with MTB. The emergence and worldwide
spread of multidrug-resistant strains of MTB mandates the
development of more effective preventive and therapeutic
tools [4]. Studies using T cell receptor transgenic mice spe-
cific for Ag85B-derived CD4+ T cells epitope which is one
of the most useful animal model for understanding host
defense mechanisms against MTB clearly demonstrated
that the MTB-susceptible APCs including DC and macro-
phages need 7–10 days to initiate activating type 1 CD4+ T
cells and CD8+ T cells in regional lymph nodes after
aerosol MTB infection, and the stimulated T cells need
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4–5 weeks to initiate inhibiting the growth of MTB in pri-
mary mice [5,6]. However, after the adequate activation of
both subsets of T cells, the number of MTB residing in the
lung remains stable [5,6]. These observations clearly dem-
onstrate that type 1 T cells are essential elements in inhibit-
ing the multiplication of MTB and also that lack of
memory type T cells capable of reacting to MTB-infected
APCs strongly and immediately allows MTB to multiply.
In addition to the animal studies, in vitro studies using hu-
man APCs or T cells reveal that host defense against MTB
is conducted chiefly by type 1 CD4+ T cells and CD8+ T
cells [7-9]. Among them, IFN-γ produced from both sub-
sets of T cells is considered as one of the most important
element for mycobacteriocidal action [10], and cytotoxic T
lymphocytes differentiated from the activated CD8+ T cells
act chiefly at late stage of MTB infection [1,11,12]. The
killing process of MTB-infected APCs is via a granule-
dependent mechanism [13,14]. Although BCG has been
used as a vaccine against tuberculosis widely, BCG cannot
prevent the manifestation of adult lung tuberculosis [15].
The major reason why BCG is not fully functional, remains
to be elucidated. BCG, as a vaccine, is not convincing in
terms of T cell activation, since BCG activates naïve CD4+
T cells substantially, but poorly activates naïve CD8+ T cells
[16,17]. The reason why BCG cannot activate naïve T cells
fully, may be based on the lack of the ability to induce
phagosomal maturation [18-20]. Therefore, improvement
of T cell-stimulating ability of BCG is strongly required.
Presently various new protein vaccine candidates have
been selected for clinical trials [18-20]. Actually the vaccine
candidates including early secretory antigenic target-6, cul-
ture filtrate protein 10, Ag85 family and polyprotein Ag
designated Mtb72F and a fusion protein ID93 [9,21-26] are
produced based on Ags that are recognized in infected in-
dividuals. However, fully reliable new vaccine has not been
established yet.
Recently, we have produced recombinant BCG, termed
BCG-DHTM which strongly activated human naïve CD4+
T cells and naïve CD8+ T cells, and, in mice, produced T
cells responsive to H37Rv-derived cytosolic protein [27].
In the production of BCG-DHTM, we employed two in-
dependent strategies in order to overcome the intrinsic
defect of BCG, that is an ability to block phagosome mat-
uration to inhibit processing of Ag and presentation to
type 1 T cells. One of the strategies is inactivation of ureC
gene of BCG, which encodes urease, from BCG [19,20].
The urease produces ammonia from urea and inhibits the
phagosomal acidification. The urease depletion facilitates
the translocation of BCG to lysosome, and enhanced the
ability of BCG to activate human naïve CD4+ T cells
[19,20]. The other one is the intracellular secretion of
antigenic molecule. As the key antigen, we used MMP-
II, since MMP-II is recognized by human T cells after
infection with M. leprae or BCG, and can ligate Toll like
receptor (TLR)2 and consequently activate both DC and
macrophages [28-31]. Also we used HSP70, since HSP70
has a chaperon activity and can prime cytotoxic T lympho-
cytes. The intraphagosomal secretion of HSP70-MMP-II
fusion protein induced strong activation of naïve CD4+ T
cells and CD8+ T cells [32]. Since both strategies, that is
urease depletion and an intracellular secretion of HSP70-
MMP-II fusion protein, worked synergistically in terms of
T cell activation, the gene encoding the HSP70-MMP-II fu-
sion protein was introduced into urease-depleted rBCG
(BCG-ΔUT-11-3) for production of BCG-DHTM [27].
Although BCG-DHTM activated both subsets of T
cells to produce IFN-γ, production of memory T cells
capable of responding to MTB-derived molecules which
can be induced chiefly in the activating phase of MTB
growth, is needed for the tuberculosis protection. To ad-
dress this point, we selected CysO (Rv1335 or CFP10A)
as the target gene, since CysO also participates in
cysteine biosynthesis pathway in MTB [33]. MTB has
two independent cysteine biosynthesis pathways, namely
the conventional pathway and the alternative pathway.
CysO is engaged in the alternative pathway. This pathway
is more advantageous under the oxidative conditions. In-
deed, CysO expression is induced under diamide stress,
one of the oxidative stress conditions [34]. This implies
that CysO may be essential for MTB to survive within
macrophages, since MTB is exposed to oxidative stress in
macrophages [35]. Furthermore, CysO expression is re-
pressed in hypoxic condition and induced in reaeration
condition, indicating that CysO may be essential for MTB
in the growth phase [36]. Moreover CysO is categorized
under ubiquitin superfamily, and may direct protein to-
wards proteasome degradation pathway, which is essential
for many cellular processes [37]. Therefore, the CysO in-
volvement in improved cellular response against MTB
within macrophages or in growth phase was considered.
In this study, we introduced CysO gene in combination
with HSP70-MMP-II fusion gene into urease-deficient
BCG-ΔUT-11-3, and produced new rBCG termed BCG-
dHCM, and evaluated its T-cell stimulating activities.
Methods
Preparation of cells and Ags
Peripheral blood was obtained from healthy PPD-positive
individuals under informed consent. The study was ap-
proved by the ethics committee of the National Institute
of Infectious Diseases, Tokyo. In Japan, BCG vaccination
is compulsory for children (0 ~ 1 year-old). Peripheral
blood mononuclear cells (PBMCs) were isolated using
Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and
cryopreserved in liquid nitrogen until use, as previously
described [38]. The viability of T cells obtained from
cryopreserved PBMCs was more than 90% and no selec-
tion in terms of functionality was induced in both
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monocytes, a precursor of DC and macrophages, and T
cells. For the preparation of peripheral monocytes,
CD3+ T cells were removed from either freshly isolated
heparinized blood, or cryopreserved PBMCs using immu-
nomagnetic beads coated with anti-CD3 monoclonal
antibody (mAb) (Dynabeads 450; Dynal Biotech, Oslo,
Norway). The CD3− PBMC fraction was plated on tissue
culture plates and the non-plastic adherent cells were re-
moved by extensive washing. The remaining adherent
cells were used as monocytes [39]. Monocyte-derived
DC were differentiated as described previously [38,40].
Briefly, monocytes were cultured in the presence of
50 ng of rGM-CSF (Pepro Tech EC LTD, London,
England) and 10 ng of rIL-4 (Pepro Tech) per ml [40].
On day 4 of culture, immature DC were infected with
rBCG at an indicated multiplicity of infection (MOI)
and, on day 6 of culture, DC were used for further ana-
lyses of surface Ag and for mixed lymphocyte assays.
Macrophages were differentiated as described previ-
ously [41,42]. In brief, monocytes were cultured in the
presence of 10 ng of rM-CSF (R & D Systems, Inc., Min-
neapolis, MN) per ml. On day 5 of culture, macrophages
were infected with rBCG at an indicated MOI and, on
day 7 of culture, they were used for further analyses of
surface Ag and mixed lymphocyte assay. The rMMP-II
protein was produced as described previously [28,43],
and the CysO protein was produced in an LPS-free
condition by using M. smegmatis. Polyclonal Ab against
CysO was produced by immunizing rabbit with the re-
combinant protein. The rHSP70 protein was purchased
(Hy Test Ltd., Turku, Finland) and H37Rv-derived cyto-
solic protein was produced as described previously [43].
Vector construction and preparation of rBCG
The genomic DNAs were obtained from BCG substrain
Tokyo and from MTB H37Rv strain. The oligonucleo-
tide primers used for the amplication of hsp70 gene
were F-Mb70Bal (5′-aaaTGGCCAtggctcgtgcggtcggg-3′)
and R-Mb70Eco (5′-aaaGAATTCcttggcctcccggccg-3′).
MMP-II sequence from MTB genomic DNA was ampli-
fied with primers: F-MMP TB Eco (aattGAATTCatgca
aggtgatcccgatgt) and R-MMP TB Sal (5′-aattGTCGACt-
caggtcggtgggcgaga). CysO sequence from MTB genomic
DNA was amplified with primers: F-CysO (5′-ggccg
ggaggccaagaacgtcaccgtatccattcc-3′) and R-CysO: (5′-at
cgggatcaccttgcccaccggccacggcgggga-3′). The amplified
HSP70 and MMP-II sequence were digested with appro-
priate restriction enzymes and cloned into parental
pMV261H plasmid. For the cloning of CysO sequence
into pMV261, In-Fusion HD cloning kit (Clontech la-
boratories, Mountain View, CA) was used. For replacing
kanamycin resistance gene to hygromycin resistance
cassette, the Xba I-Nhe I fragment from pYUB854 [44]
was cloned into Spe I-Nhe I fragment of the plasmid
[44]. The rBCG (BCG-ΔUT-11) of which ureC gene was
disrupted, was produced as described previously [20].
The hygromycin cassette in the BCG-ΔUT-11 was re-
moved by using pYUB870 encoding γδ-resolvase (γδ-tnpR)
[44]. The unmarked BCG was named BCG-ΔUT-11-3.
The HSP70-CysO-MMP II fusion protein expressing vec-
tor was introduced into BCG-ΔUT-11-3 by electroporation
method. BCG-ΔUT-11-3 containing pMV-HSP70-CysO-
MMP-II as an extrachromosomal plasmid is referred to as
BCG-dHCM, and that containing pMV-261-hygromycin
is referred to as BCG-261H (BCG vector control). Re-
combinant BCGs and MTB H37Rv strain were grown to
log phase, and stored at 108 colony forming unit (CFU)/
ml at −80°C. Before infection to DC and macrophages,
BCGs were counted by colony assay method. There is
no significant difference in the in vitro culture growth
between BCG-261H and BCG-dHCM.
Analysis of cell surface Ag
The expression of cell surface Ag on DC was analyzed
using FACSCalibur (BD Bioscience, San Jose, CA).
Dead cells were eliminated from the analysis by stain-
ing with propidium iodide (Sigma-Aldrich, St. Louis,
MO) and 1 × 104 live cells were analyzed. For the ana-
lysis of the cell surface Ag, the following mAbs were
used: FITC-conjugated mAb against HLA-ABC (G46-
2.6, BD Bioscience), HLA-DR (L243, BD Bioscience),
CD86 (FUN-1, BD Bioscience), and CD83 (HB15a,
Immunotech, Marseille, France).
APC function of DC
The ability of DC infected with BCG or pulsed with re-
combinant protein and BCG-infected macrophages to
stimulate T cells was assessed using an autologous APC-
T cell co-culture as previously described [40,45]. Purifi-
cation of CD4+ and CD8+ T cells was conducted by
using negative-isolation kits (Dynabeads 450, Dynal Bio-
tech) [40]. The purity of the CD4+ and CD8+ T cells was
more than 95% when assessed using FACSCalibur. Naïve
CD4+ and CD8+ T cells were produced by further treat-
ment of these T cells with mAb to CD45RO, which were
followed by beads coated with goat anti-mouse IgGs Ab
(Dynal Biotech). The purity of both subsets of naïve T
cells was more than 97%. However, there was no con-
tamination of memory type T cells in the naïve T cell
preparations. More than 98% of CD45RA+ T cells was
positive in the expression of CCR7 molecule. Memory
type T cells were similarly produced by the treatment of
cells with mAb to CD45RA Ag. The purified responder
cells (1 × 105 per well) were plated in 96-well round-
bottom tissue culture plates, and APCs infected with
rBCG or pulsed with protein were added to give the indi-
cated APC: T cell ratio. Supernatants of APC-T cell co-
cultures were collected on day 4 and the cytokine levels
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were determined. In some cases, rBCG-infected DC and
macrophages were treated with mAb to HLA-ABC (W6/
32, Mouse IgG2a, kappa), HLA-DR (L243, Mouse IgG2a,
kappa), CD86 (IT2.2, Mouse IgG2b, kappa, BD Biosci-
ences) or normal mouse IgG. Also, in some cases, imma-
ture DC and macrophages were treated with 50 μM of
chloroquine (Sigma-Aldrich) for 2 h and subsequently in-
fected with BCG-dHCM. The optimal dose of the Abs
and reagents was determined in advance.
Measurement of cytokine production
Levels of the following cytokines were measured; IFN-γ
produced by CD4+ and CD8+ T cells, and IL-12p70, IL-
12p40, TNFα, IL-1β and GM-CSF produced by DC or
macrophages stimulated for 24 or 48 h with rBCGs. The
concentrations of these cytokines were quantified using
the enzyme assay kits, Opt EIA Human ELISA Set (BD
Bioscience).
Animal studies
For inoculation into mice, rBCG and MTB H37Rv strain
were cultured in Middlebrook 7H9 medium supple-
mented with Middlebrook ADC enrichment to log
phase and stored at 108 CFU/ml at −80°C. Before the al-
iquots were used for inoculation, the concentration of
viable bacilli was determined by plating on Middlebrook
7H10 agar plate supplemented with Middlebrook OADC
enrichment. Three 5-week-old C57BL/6 J mice (Clea
Japan Inc., Tokyo, Japan) per group were inoculated sub-
cutaneously with 0.1 ml of PBS or PBS containing 1 × 103
rBCGs. The animals were kept in specific pathogen free
conditions and were supplied with sterilized food and
water. Four or 12 weeks after inoculation, the spleens were
removed and the splenocytes were suspended at a concen-
tration of 2 × 106 cells per ml in culture medium. The
splenocytes were stimulated with an indicated concentra-
tion of rMMP-II, rHSP70 (HyTest), rCysO or H37Rv-
derived cytosolic protein in triplicates in 96-well round
bottom microplates [20,30]. The individual culture super-
natants were collected 3–4 days after stimulation and
IFN-γ was measured using Opt EIA Mouse ELISA Set
(BD Bioscience). For observing the effect of BCG vaccin-
ation on MTB infection, five C57BL/6 mice per group
were vaccinated with 1 × 103 CFU/mouse either BCG-
261H or BCG-dHCM for 6 weeks, and were challenged
with 100 CFU/lungs of H37Rv by aerosol infection using
an automated inhalation exposure apparatus (Glas-Col
Corp., IN, Model 099C A4212). Six weeks later, bacterial
burden in lungs and spleen was assessed by mechanical
disruption in PBS with 0.05% v/v Tween 80 and enumer-
ated by colony assay. Animal studies were reviewed and
approved by the Animal Research Committee of Experi-
mental Animals of the National Institute of Infectious Dis-
eases, and were conducted according to their guidelines.
Statistical analysis
Student’s t-test was applied to determine the statistical
differences.
Results
Immunological characterization of rCysO protein
Since rCysO protein produced in M. smegmatis revealed
a single band on SDS-PAGE electrophoresis and con-
firmed by Western blot analysis using polyclonal Ab to
CysO (not shown), the immunostimulatory activities of
rCysO protein were assessed using rMMP-II of MTB as
a positive control. We assessed the activation of APCs
from the aspect of phenotypic changes and cytokine pro-
duction (Figure 1). The stimulation of immature DC
with rCysO protein up-regulated the expression of MHC
molecules, CD86, and CD83 Ags, comparable to rMMP-
II protein (Figure 1a). Further, both rMMP-II and rCysO
proteins induced IL-12p40 production from DC and
TNFα production from macrophages to a similar level
(Figure 1b). These results indicate that CysO protein has
an ability to activate APCs. When we pulsed immature
DC with rMMP-II or rCysO protein and used as a stimu-
lator of autologous CD4+ T cells, both proteins induced
IFN-γ production from not only memory type CD4+ T
cells, but also from naïve CD4+ T cells with the help of
CD40-CD40L interaction. The concentration of IFN-γ re-
leased from CD4+ T cells by the stimulation with rMMP-
II and rCysO was comparable (Figure 1c). Therefore,
rCysO protein was found to possess immunostimulatory.
We also examined if the newly produced recombinant
BCG-dHCM secretes the HSP70-CysO-MMP-II fusion
protein by using Western blot analyses. When probed by
the Ab to either of HSP70, CysO or MMP-II, BCG-
dHCM showed distinct band at 95 kD equivalent to the
molecular mass of the fusion protein comprising HSP70,
CysO and MMP-II (not shown).
Activation of Ag-presenting cells by BCG-dHCM
In order to activate naïve T cells and produce memory
type T cells efficiently, rBCG should also activate APC
adequately. We assessed the activation of DC from the
aspects of cytokine production and phenotypic changes
(Figure 2). BCG-dHCM stimulated DC to produce IL-
12p70, TNFα and IL-1β more efficiently than BCG-
261H at both MOIs: 0.25 and 0.50 (Figure 2a). To assess
the phenotypic changes induced by BCG-dHCM infec-
tion, we assessed the expression of MHC, CD86 and
CD83 molecules on DC (Figure 2b). Both BCG-261H
and BCG-dHCM up-regulated the expression of these
molecules, but the infection with BCG-dHCM induced
higher level of the expression. We used various dose of
rBCGs for the assessment, and the similar changes were
observed (not shown). Further, the stimulation of macro-
phages with BCG-dHCM induced the production of
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Figure 1 Activation of APCs by rCysO in terms of phenotypic
changes and cytokine production. a. Up-regulated expression of
APC-associated molecules on DC by stimulation with rCysO protein.
Monocyte-derived immature DC were stimulated with either rMMP-II
or rCysO protein at 10 μg/ml, and cultured for another 2 days in the
presence of rGM-CSF and rIL-4. The DC from day 6 were gated and
analyzed. Dotted lines, isotype-matched control IgG; solid lines, the
indicated test mAb. Representative results of three separate
experiments are shown. The number at the top right-hand corner of
each panel represents the difference in mean fluorescence intensity
between the control IgG and the test mAb. b. Cytokine production
from APCs by stimulation with rCysO protein. DC produced using
rGM-CSF and rIL-4 and macrophages differentiated from monocytes by
using M-CSF were stimulated with either rMMP-II or rCysO protein for
24 h. c. IFN-γ production from CD4+ T cells by stimulation with rCysO
protein. Monocyte-derived DC were stimulated with either rMMP-II or
rCysO protein, and were used as a stimulator of memory type or naïve
CD4+ T cells in a 4-day culture. 105 responder T cells were stimulated
with the protein-pulsed DC at T: DC = 10: 1. In case of the stimulation
of naïve CD4+ T cells, the protein-pulsed DC were further treated with
1.0 μg/ml of rCD40 ligand for 24 h. The concentration of the indicated
cytokine was determined by the ELISA method. A representative
of three separate experiments conducted by using 3 different
PBMCs-donors is shown. Assays were performed in triplicate and
the results are expressed as the mean ± SD. Titers were statistically
compared using Student’s t-test.
Figure 2 Activation of APCs by BCG-dHCM. a. Cytokine
production from DC by stimulation with BCG-dHCM. DC produced
using rGM-CSF and rIL-4 were stimulated with either BCG-261H or
BCG-dHCM for 24 h. b. Up-regulation of APC-associated molecules
and activation marker on DC by infection with BCG-dHCM.
Monocyte-derived immature DC were infected with either BCG-261H
or BCG-dHCM at an MOI 0.25 and cultured for another two days in
the presence of rGM-CSF and rIL-4. The DC from day 6 of culture
were gated and analyzed. Dotted lines, isotype-matched control IgG;
solid lines, the indicated test mAb. The number at the top right
corner of each panel represents the difference in the fluorescence
intensity between the control IgG and the test mAb. c. Cytokine
production from macrophages by stimulation with BCG-dHCM.
Macrophages differentiated from monocytes by using M-CSF were
stimulated with either BCG-261H or BCG-dHCM for 24 h. The
concentration of the indicated cytokine was determined by the
ELISA method. A representative of three separate experiments
conducted by using 3 different PBMCs-donors is shown. Assays were
performed in triplicate and the results are expressed as the mean ±
SD. Titers were statistically compared using Student’s t-test.
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higher level of IL-12p40, IL-1β, TNFα and GM-CSF
than that with BCG-261H at both MOIs: 0.25 and 0.50
(Figure 2c).
Activation of naïve and memory type T cells by
BCG-dHCM
The ability of BCG-dHCM to activate naïve CD4+ T cells
through DC was evaluated using BCG-261H as a control
(Figure 3). BCG-dHCM more efficiently activated naïve
CD4+ Tcells than BCG-261H to produce IFN-γ (Figure 3a).
The IFN-γ production from naïve CD4+ T cells by BCG-
dHCM stimulation seems to be induced by an Ag-specific
manner, since the treatment of the surface of BCG-dHCM-
infected DC with mAb to HLA-DR or CD86 showed 90%
inhibition (Figure 3b). Further, pretreatment of immature
DC with chloroquine prior to infection with BCG-dHCM,
inhibited the production of IFN-γ from naïve CD4+ T cells
(Figure 3c). These results suggest that the phagosomal
maturation is induced by BCG-dHCM infection and is
closely associated with the activation of naïve CD4+ T
cells. Previously, we reported that only when the urease-
deficient rBCG, but not normal BCG, was used as a host
BCG and introduced with genes encoding antigenic
molecules, the rBCG could activate memory type CD4+ T
cells through M-CSF-dependent macrophages [27]. We
checked whether BCG-dHCM activates memory type
CD4+ T cells, and found that BCG-dHCM induced the
significant production of IFN-γ from the responder popu-
lation (Figure 4a). Again, the activation of memory type
CD4+ T cells by BCG-dHCM-infected macrophages seems
to be dependent on the expression of MHC class II and
CD86 Ags, since the treatment of rBCG-infected mac-
rophages with mAb to HLA-DR or CD86 inhibited the
IFN-γ production significantly (Figure 4b). Further, the
treatment of macrophages with chloroquine prior to
BCG-dHCM infection, inhibited IFN-γ production by
memory type CD4+ T cells (Figure 4c). Next, we assessed
whether BCG-dHCM could activate naïve CD8+ T cells
when DC were enrolled as APC (Figure 5). While vector
control BCG did not induce the activation of naïve CD8+
T cells as reported [19,20], BCG-dHCM induced significant
level of activation of naïve CD8+ T cells (Figure 5a). A
significant concentration of IFN-γ can be released from
naïve CD8+ T cells. Also the mAb treatment of BCG-
dHCM-infected DC with anti-HLA-ABC Ab or anti-CD86
Ab significantly inhibited the IFN-γ production from naïve
CD8+ T cells (Figure 5b), and pre-treatment of immature
DC with chloroquine, again, inhibited the cytokine produc-
tion from the responder (Figure 5c). These results suggest
that BCG-dHCM can activate not only naïve CD4+ T cells,
but also naïve CD8+ T cells through DC, and also activate
memory CD4+ T cells through macrophages in an Ag-
dependent manner. Further, the phagosomal maturation is
closely associated with the T cell activation.
Figure 3 Activation of naïve CD4+ T cells by BCG-dHCM
through activation of DC. a. IFN-γ production from naïve CD4+ T
cells by stimulation with BCG-dHCM. Monocyte-derived DC were
infected with either BCG-261H or BCG-dHCM at the indicated MOI,
and were used as a stimulator. 105 responder naïve CD4+ T cells were
stimulated with the rBCG-infected DC at T: DC = 10: 1. b. Inhibition of
T cell activation by the treatment of BCG-dHCM-infected DC with
mAb. DC were infected with BCG-dHCM at the indicated MOI, and
subsequently treated with 10 μg/ml of the mAb or normal murine IgG.
These APCs were used as the stimulator of the indicated responder
T cells (1 × 105/well) at the indicated T/DC ratios for 4 days. IFN-γ
produced by T cells was measured. c. Effect of chloroquine treatment
of DC on the activation of T cells. Immature DC were treated with
chloroquine (50 μM, 2 h) or untreated, and subsequently infected with
BCG-dHCM at the indicated MOI. These DC were used as the stimulator
of the indicated responder T cells at the indicated responder/stimulator
ratios. IFN-γ produced by T cells was measured. A representative
of three separate experiments conducted by using 3 different
PBMCs-donors is shown. Assays were performed in triplicate and
the results are expressed as the mean ± SD. Titers were statistically
compared using Student’s t-test.
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Figure 4 Activation of memory-type CD4+ T cells by BCG-dHCM
through activation of macrophages. a. IFN-γ production from
memory type CD4+ T cells by stimulation with BCG-dHCM.
Macrophages differentiated by using M-CSF were infected with
either BCG-261H or BCG-dHCM at the indicated MOI, and were used
as a stimulator of responder CD4+ T cells in a 4-day culture. 105
responder T cells were stimulated with the rBCG-infected
macrophages at T: macrophage = 10: 1. b. Inhibition of T cell
activation by the treatment of BCG-dHCM-infected macrophages
with mAb. Macrophages were infected with BCG-dHCM at the
indicated MOI, and subsequently treated with 10 μg/ml of the mAb
or normal murine IgG. These APCs were used as the stimulator
of the indicated responder T cells (1 × 105/well) at the indicated
T/macrophages ratios for 4 days. IFN-γ produced by T cells was
measured. c. Effect of chloroquine treatment of macrophages on
the activation of T cells. Macrophages were treated with chloroquine
(50 μM, 2 h) or untreated, and subsequently infected with BCG-
dHCM at the indicated MOI. These macrophages were used as
the stimulator of the indicated responder T cells at the indicated
responder/stimulator ratios. IFN-γ produced by T cells was measured.
A representative of three separate experiments conducted by using
3 different PBMCs-donors is shown. Assays were performed in
triplicate and the results are expressed as the mean ± SD. Titers were
statistically compared using Student’s t-test.
Figure 5 Activation of naive CD8+ T cells by BCG-dHCM
through activation of DC. a. IFN-γ production from naïve CD8+
T cells by stimulation with BCG-dHCM. DC were infected with either
BCG-261H or BCG-dHCM at the indicated MOI, and were used as a
stimulator. 105 responder T cells were stimulated for 4 days with
rBCG-infected DC at T: DC = 10: 1. b. Inhibition of T cell activation
by the treatment of BCG-dHCM-infected DC with mAb. DC were
infected with BCG-dHCM at the indicated MOI, and subsequently
treated with 10 μg/ml of the mAb or normal murine IgG. These
APCs were used as the stimulator of the indicated responder T cells
(1 × 105/well) at the indicated T/DC ratios for 4 days. IFN-γ produced
by T cells was measured. c. Effect of chloroquine treatment of
DC on the activation of T cells. Immature DC were treated with
chloroquine (50 μM, 2 h) or untreated, and subsequently infected
with BCG-dHCM at the indicated MOI. These DC were used as the
stimulator of the indicated responder T cells at the indicated
responder/stimulator ratios. IFN-γ produced by T cells was measured.
A representative of three separate experiments conducted by using
3 different PBMCs-donors is shown. Assays were performed in
triplicate and the results are expressed as the mean ± SD. Titers were
statistically compared using Student’s t-test.
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Production of T cells responsive to the secondary
stimulation by BCG-dHCM in vivo
The ability of BCG-dHCM to produce T cells highly re-
sponsive to the secondary in vitro stimulation was exam-
ined by in vivo functional studies (Figure 6). C57BL/6
mice were subcutaneously inoculated with 1 × 103 CFU/
mouse of either BCG-261H or BCG-dHCM 4 weeks be-
fore stimulation in vitro (Figure 6a). Not only MMP-II,
HSP70 and CysO of which encoding genes were intro-
duced into BCG-dHCM, but also H37Rv-derived cytosolic
protein were used as a secondary in vitro stimulator. The
T cells from mice inoculated with BCG-dHCM respond
more vigorously to all stimulators and produced higher
concentration of IFN-γ (Figure 6a) and IL-2 (not shown)
than T cells from mice uninfected or infected with BCG-
261H. To examine the long-term effect of the inoculation
of BCG-dHCM on the production of responsive T cells,
C57BL/6 mice were subcutaneously inoculated with 1 ×
103 CFU/mouse of either BCG-261H or BCG-dHCM
12 weeks before restimulation in vitro (Figure 6b). Again,
a significantly higher concentration of IFN-γ was pro-
duced from splenic T cells obtained from mice inoculated
with BCG-dHCM by all stimulators than those from mice
uninfected or infected with BCG-261H.
Effect of BCG-dHCM vaccination on the multiplication of
aerosol challenged M. tuberculosis
C57BL/6 mice vaccinated with either BCG-261H or BCG-
dHCM (1 × 103 CFU/mouse) for 6 weeks were challenged
with 100 CFU per lungs of H37Rv by aerosol infection.
Six weeks later, the MTB recovered from both lungs and
spleen was enumerated (Figure 7). While the mice vac-
cinated with BCG-261H minimally inhibit the multipli-
cation of MTB, the vaccination with BCG-dHCM
significantly inhibited the growth of H37Rv in lungs
(Figure 7a). Similarly, the multiplication of MTB in
spleen is significantly inhibited by the vaccination with
BCG-dHCM (Figure 7b).
Figure 6 Production of T cells responsive to the secondary stimulation in mice by infection with BCG-dHCM. Three 5-week-old C57BL/6
mice per group were each infected with 1 × 103 CFU of either BCG-261H or BCG-dHCM subcutaneously. Four (a) or 12 (b) weeks after the
inoculation, splenocytes (2 × 105 cells/well) were stimulated with the indicated stimulators for 4 days in vitro, and IFN-γ produced in the cell
supernatant was measured. Assays were performed in triplicate for each mouse, and the results of three mice per group are shown as the
mean ± SD. Representative results of three separate experiments are shown. Titers were statistically compared using Student’s t-test.
Figure 7 Inhibition of MTB multiplication by subcutaneous vaccination with BCG-dHCM. Five-week-old C57BL/6 mice (5 mice/group) were
subcutaneously vaccinated with 1 × 103 CFU/mouse of either BCG-261H or BCG-dHCM and were challenged with 100 CFU/lungs of H37Rv by
aerosol infection, at 6 weeks post vaccination. The number of MTB recovered from the lung (a) or spleen (b) at 6 weeks post challenge was
enumerated by colony assay method. Representative results of three separate experiments are shown. Titers were statistically compared using
Student’s t-test.
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Discussion
IFN-γ produced by activated type 1 CD4+ T cells and
CD8+ T cells has an essential function in both antimicro-
bial activity against MTB and limitation of lung inflamma-
tion associated with massive accumulation of neutrophils
which are recruited by Th17 cells [7-9,46]. Therefore, one
of the important aims of vaccination is to produce mem-
ory type CD4+ T cells as well as memory type CD8+ T cells
capable of producing abundant dose of IFN-γ by respond-
ing rapidly to MTB-infected DC and macrophages. From
the studies using T cell receptor-transgenic animal model,
it is known that it needs several weeks for host T cells to
start inhibiting the multiplication of aerosol infected MTB
in primary mice [5,6]. It is unknown whether alveolar
APCs could be primed by vaccination, so that time re-
quired for APC to move to the regional LN after phago-
cytosing MTB in lung could be reduced. However, it
could certainly reduce the time necessary for T cells to be
activated by the interaction with MTB-infected APCs in
the LN by differentiating naïve T cells into memory subset
by vaccination. BCG has been used widely as a vaccine
against tuberculosis, but its effect is quite limited. BCG
can only prevent the development of miliary tuberculosis
and tuberculosis meningitis in child, but is not effective
for prevention of adult lung tuberculosis [15]. However,
BCG has many antigenic molecules common to that
present in MTB, and moreover, the safety of BCG is well
established [16,17]. Thus, we are of the opinion that the
improvement of BCG by producing rBCGs would be the
fastest route to produce more reliable single injection vac-
cine against tuberculosis. In this respect, rBCG should
have some antigenic molecules which are present in MTB,
and also should highly activate not only naïve T cells of
both CD4 and CD8 subsets, but also APCs including DC
and macrophages. Since both DC and macrophages ex-
press MMP-II-related peptide on their surface upon an
infection with both H37Ra and H37Rv [31], and also
MMP-II can ligate TLR2 and consequently activates NF-
κB pathway of APCs [28-31], MMP-II is considered to
be good target that could be used as an active vaccinat-
ing agent. In this study, we produced new rBCG termed
BCG-dHCM, that is a urease-deficient rBCG that se-
crete the fusion protein composed of HSP70, CysO and
MMP-II. In the production of BCG-dHCM, we used
MMP-II as a central component, HSP70 as an adjuvant,
and CysO as an element necessary to release Ag in
APCs. BCG-dHCM secreted the fusion protein in both
lysosome in which abundant enzyme is available and in
phagosomes of BCG-susceptible cells. Thus BCG-dHCM
strongly activated both subsets of naïve T cells and APCs.
The efficient activation of APCs by BCG-dHCM is re-
vealed through up-regulation of APC-associated molecules
and by enhanced production of various proinflammatory
cytokines including IL-12, IL-1β and TNFα from DC and
macrophages. The efficient activation of these APCs can be
assumed to be directly linked with the effective activa-
tion of adaptive immunities. Actually macrophages-
infected with BCG-dHCM activated memory type CD4+
T cells. Previous rBCG termed BCG-70M that is BCG
introduced with HSP70-MMP-II fusion gene failed to
activate memory type T cells through macrophages [32],
thus, the high immunostimulatory function of BCG-
dHCM seems to be owing to the high antigenic load on
the surface of BCG-dHCM-infected macrophages, that
is due to efficient translocation of BCG-dHCM into lyso-
some. The effective memory T cells are ones capable of
responding to the molecules expressed on the surface of
MTB-infected APCs, and are produced by activating naïve
T cells in an Ag-specific manner [27,31]. In this respect,
the activation of both naïve CD4+ T cells and naïve CD8+
T cells by BCG-dHCM was dependent on MHC and
CD86 molecules expressed on APCs. Thus, BCG-dHCM
seems to be stimulating naïve T cells in an Ag-specific
fashion. Presumably, APCs infected MTB express various
epitopes on their surface, indicating that the presence of
clonal diversity of T cells, might provide better control of
MTB. Subcutaneous inoculation of BCG-dHCM into
C57BL/6 mice produced long lasting T cells responsive to
in vitro secondary stimulation. Upon stimulation with not
only MMP-II, CysO and HSP70, but also H37Rv-derived
cytosolic (Figure 6) and membrane (not shown) protein, T
cells obtained from mice inoculated with BCG-dHCM
were efficiently reactivated and produced high concentra-
tion of IFN-γ. Although the exact reason why these T cells
were capable of responding to MTB components is not
clear, it may be reasonable to speculate that the transloca-
tion of BCG-dHCM into lysosome induced the degrad-
ation of BCG that leads to production of epitope derived
from BCG itself. CysO is engaged in alternative cysteine
biosynthesis pathway, which plays an essential role for the
MTB survival in the oxidative condition [33,34]. Also,
CysO is categorized in ubiquitin superfamily and is pos-
sible to direct protein towards proteosome degradation
pathway [37]. In fact, in this study, we found that rCysO,
produced by using M. smegmatis in a LPS-free condition,
activated both innate and adaptive cellular responses,
since it induced some cytokine production from APCs
and phenotypic changes in DC, and also stimulated IFN-γ
production from both subsets of T cells. When we intro-
duced CysO gene into urease-deficient rBCG accom-
panying with HSP70-MMP-II fusion gene, CysO was
produced as a part of fusion protein, in fact, the im-
munogenic function of CysO may be up-regulated be-
cause of the chaperone activity of HSP70, that may lead
to production of CysO-specific memory T cells in vivo,
although we could not elucidate the detailed mecha-
nisms of the immunological function of CysO. Actually,
mice inoculated with BCG-dHCM produced T cells that
Tsukamoto et al. BMC Infectious Diseases 2014, 14:179 Page 9 of 11
http://www.biomedcentral.com/1471-2334/14/179
respond to CysO vigorously. These results indicate that
CysO protein was certainly secreted from rBCG in APC
and was used for T cell activation. CysO expression in
MTB is inhibited in hypoxic condition and is induced
by reaeration [34], thus, CysO may be highly expressed
in MTB in active phase, and, also, is involved in the sur-
vival of MTB in macrophages. Therefore, production of
CysO reactive T cells may be advantageous for the in-
duction of host defense reaction against MTB which is
re-activated in macrophages. In this study, we used
small dose of BCG, one fifth of usual dose [47], and by
which the parent BCG cannot inhibit MTB growth in
lungs in our hands (not shown), for vaccination of mice
in order to elucidate the difference between BCG-261H
and BCG-dHCM. As expected BCG-261H did not in-
hibit the MTB growth, but even a small dose of BCG-
dHCM at least partially inhibits multiplication of MTB
in both lungs and spleen. In this respect, BCG-dHCM
seems to be superior to BCG-261H. The reason why
BCG-261H did not inhibit the multiplication of MTB
may be because we tested bacterial burden in lung and
spleen at 6 wks, but not 4 wks which is a frequently
used time point [47], after MTB challenge, because re-
port suggests that 4 ~ 5 wks are necessary to reach the
stable level of pulmonary bacterial burden even in naïve
mice [6]. Also, due to BCG strain differences, there may
be differences in protective effect in mice experiments.
However, more detailed studies, for example, the differ-
ence between BCG-DHTM and BCG-dHCM, and the
relation between the presence of CysO-reactive T cells
and MTB replication in macrophages, are absolutely re-
quired, to prove the usefulness of CysO involvement for
the production of vaccine against tuberculosis.
Conclusions
These results indicate that the secretion of polycomponent
antigenic molecules can efficiently produce polyclonal Ag-
specific T cells responsive to secondary stimulation in vivo,
and may provide one possible tool for the development of
better vaccine against tuberculosis.
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